Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study

Contemporary Clinical Trials

Volumn 32, Issue 5, 2011, Pages 710-716

  Ruilope, Luis M ^a   Schaefer, Angie ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Amlodipine; Central arterial blood pressure; Hypertension; Olmesartan; Perindopril; SEVITENSION

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; PERINDOPRIL; PLACEBO; SEVIKAR; UNCLASSIFIED DRUG;

AORTA PRESSURE; ARTICLE; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HYPERTENSION; MULTICENTER STUDY (TOPIC); PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; RISK FACTOR; STUDY DESIGN;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AORTA; CALCIUM CHANNEL BLOCKERS; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PERINDOPRIL; RENIN-ANGIOTENSIN SYSTEM; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TETRAZOLES;

EID: 79960894456     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2011.04.011     Document Type: Article

References (18)

1. Sharman J., Stowasser M., Fassett R., Marwick T., Franklin S. Central blood pressure measurement may improve risk stratification. J Hum Hypertens 2008, 22:838-844.
2. Williams B., Lacy P.S. Central aortic pressure and clinical outcomes. J Hypertens 2009, 27:1123-1125.
3. Roman M.J., Devereux R.B., Kizer J.R., Lee E.T., Galloway J.M., Ali T., et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007, 50:197-203.
4. Agabiti-Rosei E., Mancia G., O'Rourke M.F., Roman M.J., Safar M.E., Smulyan H., et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 2007, 50:154-160.
5. Pini R., Cavallini M.C., Palmieri V., Marchionni N., Di Bari M., Devereux R.B., et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol 2008, 51:2432-2439.
6. Wang K.L., Cheng H.M., Chuang S.Y., Spurgeon H.A., Ting C.T., Lakatta E.G., et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?. J Hypertens 2009, 27:461-467.
7. Asmar R.G., London G.M., O'Rourke M.E., Safar M.E. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001, 38:922-926.
8. Boutouyrie P., Achouba A., Trunet P. EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010, 55:1314-1322.
9. London G.M., Asmar R.G., O'Rourke M.F., Safar M.E. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004, 43:92-99.
10. Matsui Y., Eguchi K., O'Rourke M.F., Ishikawa J., Miyashita H., Shimada K., et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009, 54:716-723.
11. Morgan T., Lauri J., Bertram D., Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004, 17:118-123.
12. Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton A., Collier D., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
13. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
14. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
15. Chrysant S., Melino M., Karki S., Lee J., Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008, 30:587-604.
16. Heagerty A.M., Laeis P., Haag U. Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy - additional effect by uptitration in patients with moderate-to-severe hypertension. J Hypertens 2009, 27:S283.
17. Volpe M., Brommer P., Haag U., Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009, 29:11-25.
18. Pauca A.L., O'Rourke M.F., Kon N.D. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001, 38:932-937.